Skip to main content

Table 2 Comparison between therapy-related myeloid neoplasm with and without TP53 mutation

From: TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases

  Mutated TP53 ( n= 40) Wild-type TP53 ( n= 68) p value
Age, years, median (range) 66 (23–87) 68 (18–82) 0.6491*
Male: female 22:18 40:28 0.8405
Prior therapy    
 Chemotherapy only 21 40 0.5518
 Radiation only 2 6 0.7082
 Combined chemoradiation 17 22 0.2972
Hemoglobin, g/L, median (range) 91 (66–1128) 98 (60–139) 0.1775*
Mean corpuscular volume, median (range) 90 (70–107) 93 (79–116) 0.0076*
White blood cell, × 109/L, median (range) 3.0 (0.3–41) 3.0 (0.6–93.9) 0.5314*
Absolute neutrophil count, × 109/L, median (range) 0.8 (0–9.2) 1.1 (0–30.62) 0.2223*
Platelet, × 109/L, median (range) 32 (5–394) 42 (7–364) 0.0393*
Cytogenetic data    <0.0001
 Diploid 0 16  
 Non-complex (<3) 3 30  
 Complex (≥3) 36 20  
 Not available 1 2  
 Chromosome 5 aberrations 28 14 <0.0001
 Chromosome 7 aberrations 18 23 0.2067
 Number of abnormalities, median (range) 7 (1–22) 1 (0–22) <0.0001*
  1. Asterisk (*) denotes p value was calculated by Mann-Whitney U test. All the others were calculated by Fisher’s exact test.